Table 3.
Study | i1 | i2 | i3 | i4 | i5 | i6 | i7 | i8 | i9 | i10 | i11 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Brichetto, G. et al., 2013 [48] | Yes | Yes | No | Yes | No | No | Yes | No | No | Yes | Yes | 5/10 |
Cuesta-Gómez, A. et al., 2020 [54] | Yes | Yes | No | Yes | No | No | Yes | Yes | No | Yes | Yes | 6/10 |
Khalil, H. et al., 2019 [49] | Yes | Yes | Yes | Yes | No | No | Yes | No | No | Yes | Yes | 6/10 |
Lamargue, D. et al., 2020 [50] | Yes | Yes | No | Yes | No | No | Yes | Yes | No | Yes | Yes | 6/10 |
Maggio, M.G. et al., 2020 [59] | Yes | Yes | Yes | Yes | No | No | Yes | Yes | No | Yes | Yes | 7/10 |
Ozkul, C. et al., 2020 [52] | Yes | Yes | No | Yes | No | No | No | Yes | No | Yes | Yes | 5/10 |
Prosperini, L. et al., 2013 [55] | Yes | Yes | Yes | Yes | No | No | No | Yes | No | Yes | Yes | 6/10 |
Robinson, J. et al., 2015 [56] | Yes | Yes | No | Yes | No | No | No | No | Yes | Yes | Yes | 5/10 |
Thomas, S. et al., 2017 [57] | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes | 7/10 |
Tollár, J. et al., 2019 [58] | Yes | Yes | Yes | Yes | No | No | Yes | Yes | No | Yes | Yes | 7/10 |
Tuba-Ozdogar, A. et al., 2020 [51] | No | Yes | No | Yes | No | No | No | Yes | No | Yes | Yes | 5/10 |
Yazgan, Y.Z. et al., 2020 [53] | Yes | Yes | No | Yes | No | No | No | Yes | No | Yes | Yes | 5/10 |
Abbreviations: i1 = eligibility criteria; i2 = random allocation; i3 = concealed allocation; i4 = baseline comparability; i5 = blind subjects; i6 = blind therapists; i7 = blind assessors; i8 = adequate follow-up; i9 = intention-to-treat analysis; i10 = between-group comparisons; i11 = point estimates and variability.